The BH3-mimetic venetoclax, selectively inhibiting BCL-2, often overexpressed in leukemia and lymphoma, has been approved for the treatment of refractory chronic lymphatic leukemia (CLL) [29]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.